Long before any doctor sees a tumor, the blood of healthy men may already carry faint signatures of the path their disease will take. Researchers at Oxford Population Health, drawing on stored samples from a major European cohort, have traced such signatures in proteins that separate men later diagnosed with prostate cancer from those who were not, and in some cases those whose cancer later grew aggressive. The findings, which hint at the quiet work of the immune system and the early reshaping of tissue, do not yet offer a tool for the clinic, but they open a patient look backward into the dis
Blood Proteins Linked to Future Aggressive Prostate Cancer Risk in Large Population Study
Prostate cancer is not one disease.
Mark
What's new here compared with earlier prostate cancer research?
Mimi
Scale and timing. They measured over 6,000 proteins in blood taken years before diagnosis, in 982 men who later developed cancer and 1,573 comparison men.
Luke
Worth saying what that doesn't give us: a test. The source says the associations were mostly modest and the proteins aren't suitable for clinical use.
Mark
Which proteins stood out?
Mimi
Twelve were tied to cancer diagnosed more than 15 years later, including GZMK from immune cells. Seven were tied to aggressive disease, and ANKRD1 was consistently linked to serious forms, including spread or fatal cancers.
Luke
Linked is the operative word. The immune idea, that GZMK reflects the body keeping cancer in check, is a suggestion in the reporting, not something shown.
Mark
And ERBB3, KRAS and NRAS?
Mimi
Those come from genes already known to matter in prostate cancer. The proteins were tied to aggressive cancer about a decade later. The team says that doesn't mean cancer was already present.
Luke
Also, not everything replicated. Several findings were supported by other studies and genetic evidence, but not all could be confirmed.
Mark
So what happens next?
Mimi
The PCAP programme, funded by Cancer Research UK, will examine whether these findings can improve prediction or prevention.
Luke
Whether they can is still unknown.
Der Puls
- Researchers scanned more than 6,000 blood proteins from men sampled years before any diagnosis, searching for signals that foreshadow prostate cancer.
- Twelve proteins flagged later disease, and seven pointed toward the aggressive forms that threaten lives rather than sleeping quietly.
- Immune-linked GZMK, the blood-vessel and cell-adhesion signals, and ANKRD1 stand out as the clearest clues to where danger may begin.
- The links are modest and not ready for clinical use, so the next step is testing whether these markers can truly sharpen prediction or prevention.
- Cancer Research UK-backed PCAP work is now positioned to determine whether this early biological trail becomes a practical tool.
Long before any doctor sees a tumor, the blood of healthy men may already carry faint signatures of the path their disease will take. Researchers at Oxford Population Health, drawing on stored samples from a major European cohort, have traced such signatures in proteins that separate men later diagnosed with prostate cancer from those who were not, and in some cases those whose cancer later grew aggressive. The findings, which hint at the quiet work of the immune system and the early reshaping of tissue, do not yet offer a tool for the clinic, but they open a patient look backward into the disease's beginnings.
Blood drawn from healthy men years ago is now helping researchers understand who later developed prostate cancer. A team at Oxford Population Health measured more than 6,000 proteins in stored samples from the European EPIC cohort, comparing 982 men who were later diagnosed with 1,573 men who were not. Participants were followed for around 16 years, and the work, published in European Urology, is described as the largest population-based study of its kind.
The question matters because prostate cancer is the most commonly diagnosed cancer in men worldwide, yet its causes remain poorly understood. Age and genetics cannot be changed, and many tumors grow so slowly they never cause harm, while others prove deadly. Knowing which men are heading toward aggressive disease is the difficult part.
The study identified twelve proteins linked to diagnosis more than fifteen years after sampling, including GZMK, a protein made by immune cells that help destroy abnormal cells. Its presence suggests immune activity may help hold the disease in check long before it appears. Seven proteins were tied to aggressive cancer, most notably ANKRD1, which was consistently associated with advanced and fatal forms. Other signals pointed to how cancer cells interact with surrounding tissue, to new blood vessel formation, and to proteins from known driver genes such as ERBB3, KRAS and NRAS.
The authors caution that these results do not mean cancer was already present when the blood was drawn. Several findings held up against other large studies and genetic evidence, though not all could be confirmed, and the associations remain modest. The proteins are not yet suitable as clinical tests.
Researchers involved see the work as a window into the disease's earliest biology. Cancer Research UK, which part-funded the study, is looking to the charity-backed PCAP programme to test whether these findings can genuinely improve prediction or prevention.
Blood drawn from healthy men years ago is now telling researchers something about who went on to develop prostate cancer. A team at Oxford Population Health has measured more than 6,000 proteins in those stored samples and found patterns that separate men who were later diagnosed from men who were not, including men whose disease turned aggressive.
The work, published in European Urology and presented at the American Society of Human Genetics Annual Meeting, is described as the largest population-based study to date of blood proteins and future prostate cancer risk. It drew on the European Prospective Investigation into Cancer and Nutrition, known as EPIC. The researchers compared blood samples from 982 men who subsequently developed prostate cancer with those from a randomly selected group of 1,573 men from the same cohort. Participants were followed for around 16 years.
The backdrop is a gap in knowledge. Prostate cancer is the most commonly diagnosed cancer in men worldwide, yet little is understood about why some men develop it or why some tumors become aggressive. The best-established risk factors, age and genetics, cannot be changed. Many prostate cancers grow slowly and may never cause harm, while others are life-threatening.
Twelve proteins were linked to prostate cancer diagnosed more than 15 years after the blood was collected. One was GZMK, a protein made by immune cells that help recognize and destroy abnormal cells. Its presence suggests that immune processes may help keep prostate cancer in check long before it is diagnosed.
Seven proteins were linked to aggressive disease. One of them, ANKRD1, was consistently associated with several serious forms of prostate cancer, including cancers that had spread or ultimately proved fatal. Other findings pointed to the way cancer cells interact with surrounding tissue and to the formation of new blood vessels. The study also found links with proteins produced by genes already known to matter in prostate cancer, including ERBB3, KRAS and NRAS, particularly for aggressive cancer diagnosed about a decade later. The authors stress that this does not mean cancer was already present when the blood was taken, but the results may offer clues to biological changes that come before the disease.
The team checked its results against other large population studies and genetic evidence. Several findings held up in those analyses, though not all could be confirmed. Most associations were modest, and the proteins are not yet suitable as clinical tests. Further studies are needed to show whether they could improve prediction of clinically significant prostate cancer.
Dr. Zhe Huang, the study's first author, said that measuring thousands of proteins in blood collected years before diagnosis lets researchers begin to examine how men who later develop aggressive disease differ from those who do not. Professor Karl Smith-Byrne, a senior author, said that finding proteins tied to known driver genes this early gives new insight into the disease's earliest stages and, alongside genetic evidence, may point to pathways that could be targeted to prevent aggressive cancer.
Cancer Research UK part-funded the research. Dr. Iain Foulkes, its executive director of research and innovation, called prostate cancer one of the biggest cancer killers of men and said the findings open a window into the disease's biology, including a possible role for the immune system. Professor Ruth Travis, a leader of the charity-funded Prostate Cancer Aetiology and Prevention Programme (PCAP), said technologies that measure thousands of proteins at once, combined with long-running population studies, allow researchers to look back many years before diagnosis.
PCAP's future work will test whether these findings can contribute to better ways of predicting or preventing prostate cancer.
Bemerkenswerte Zitate
Finding proteins linked to known prostate cancer driver genes in blood collected years before diagnosis gives new insights into the earliest stages of the disease.— Professor Karl Smith-Byrne, Oxford Population Health
Technologies that measure thousands of proteins simultaneously are giving unprecedented insight into the earliest stages of prostate cancer development.— Professor Ruth Travis, Oxford Population Health
Möchten Sie die ganze Geschichte?
Das Original lesen bei News-Medical ↗
Health & Medicine